Literature DB >> 20158339

Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma.

Yazhou Cui1, Tianliang Li, Denglu Zhang, Jinxiang Han.   

Abstract

It has been suggested that ezrin activation plays a key role in the regulation of cancer metastasis. In this study, we immunohistochemically investigated the expression patterns of total ezrin and its two phosphorylated forms, pEzrin(- Thr567) and pEzrin(- Tyr353), in 66 samples of invasive pancreatic carcinomas and 11 samples of normal pancreas tissues. Positive expressions of ezrin and pEzrin(- Thr567) were detected in most PDAC tissues, significantly higher than that of pEzrin(- Tyr353). Furthermore, overexpression of pEzrin(- Tyr353) in pancreatic cancers was associated with positive lymph node metastasis, less differentiation, pAkt overexpression, and shorter survival times. pEzrin(- Tyr353) may be a potent prognosis predictor for pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20158339     DOI： 10.3109/07357900903124498

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  15 in total

1.  Relative quantification of serum proteins from pancreatic ductal adenocarcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry.

Authors:  Angela Y Wehr; Wei-Ting Hwang; Ian A Blair; Kenneth H Yu
Journal:  J Proteome Res       Date:  2012-02-15       Impact factor: 4.466

2.  Epidermal growth factor-induced cellular invasion requires sphingosine-1-phosphate/sphingosine-1-phosphate 2 receptor-mediated ezrin activation.

Authors:  K Alexa Orr Gandy; Mohamad Adada; Daniel Canals; Brittany Carroll; Patrick Roddy; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2013-04-29       Impact factor: 5.191

3.  Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.

Authors:  M Bartova; J Hlavaty; Y Tan; C Singer; K Pohlodek; J Luha; I Walter
Journal:  Clin Exp Metastasis       Date:  2017-06-17       Impact factor: 5.150

Review 4.  Ezrin Orchestrates Signal Transduction in Airway Cells.

Authors:  Lei-Miao Yin; Ting-Ting Duan; Luis Ulloa; Yong-Qing Yang
Journal:  Rev Physiol Biochem Pharmacol       Date:  2018       Impact factor: 5.545

5.  Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma.

Authors:  Vesselin R Penchev; Yu-Tai Chang; Asma Begum; Theodore Ewachiw; Christian Gocke; Joey Li; Ross H McMillan; Qiuju Wang; Robert Anders; Luigi Marchionni; Anirban Maitra; Aykut Uren; Zeshaan Rasheed; William Matsui
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

6.  Ezrin expression in rectal cancer predicts time to development of local recurrence.

Authors:  Fredrik Jörgren; Mef Nilbert; Eva Rambech; Pär-Ola Bendahl; Gudrun Lindmark
Journal:  Int J Colorectal Dis       Date:  2012-01-12       Impact factor: 2.571

7.  Ezrin-expressing lung adenocarcinoma cells and podoplanin-positive fibroblasts form a malignant microenvironment.

Authors:  Shigeki Suzuki; Genichiro Ishii; Rie Matsuwaki; Shinya Neri; Hiroko Hashimoto; Chisako Yamauchi; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Mitsutomo Kohno; Kanji Nagai; Atsushi Ochiai
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-11       Impact factor: 4.553

8.  Ezrin expression and its phosphorylation in gastric carcinoma with lymphoid stroma and Epstein-Barr virus infection.

Authors:  Taro Tobo; Minako Hirahashi; Takashi Yao; Shinichi Aishima; Yoshinao Oda
Journal:  Mol Clin Oncol       Date:  2012-12-28

9.  Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Authors:  K Boman; A H Larsson; U Segersten; E Kuteeva; H Johannesson; B Nodin; J Eberhard; M Uhlén; P-U Malmström; K Jirström
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

10.  Ezrin promotes invasion and metastasis of pancreatic cancer cells.

Authors:  Yunxiao Meng; Zhaohui Lu; Shuangni Yu; Qiang Zhang; Yihui Ma; Jie Chen
Journal:  J Transl Med       Date:  2010-06-23       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.